LONDON (Alliance News) - FTSE 250-listed investment company Allied Minds PLC on Wednesday said Allied-Bristol Life Sciences LLC, its joint venture with US drugs company Bristol-Myers Squibb Co, has signed a collaboration with New York University.
Allied-Bristol has launched ißeCa Therapeutics to licence proprietary compounds from the NYU School of Medicine which will target the Wnt pathway. The Wnt pathway plays a key role in the development and progression of a number of cancers.
The agreement is the third in a series of discovery and development projects Allied-Bristol is pursuing, it said.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.